Jay Andersen, MD of Compass Oncology discusses the phase 3 KEYNOTE-522 trial was investigating KEYTRUDA (pembrolizumab), Merck"™s anti-PD-1 immunotherapy, in combination with chemotherapy that was designed for patients with TNBC.
pembrolizumab, keytruda, phase 3, keynote-522 trial, merck’s anti-pd-1 immunotherapy, immunotherapy, patients with tnbc, tnbc
Advertisement